Innovacell (TSE:504A) Debt-to-EBITDA : N/A (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:504A Innovacell Inc TSE:504A
10 GF Score
Price 円583.00
View Full Analysis

What is Innovacell Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Innovacell's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was 円117.16 Mil. Innovacell's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was 円2,057.81 Mil. Innovacell's annualized EBITDA for the quarter that ended in Jun. 2026 was 円0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Innovacell's Debt-to-EBITDA or its related term are showing as below:

TSE:504A' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.69   Med: -2.41   Max: -1.19
Current: -1.19

During the past 3 years, the highest Debt-to-EBITDA Ratio of Innovacell was -1.19. The lowest was -2.69. And the median was -2.41.

TSE:504A's Debt-to-EBITDA is ranked worse than
100% of 306 companies
in the Biotechnology industry
Industry Median: 1.255 vs TSE:504A: -1.19

Innovacell  (TSE:504A) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Innovacell Debt-to-EBITDA Related Terms

Innovacell Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Innovacell's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovacell Debt-to-EBITDA Chart

Innovacell Annual Data
Trend Dec23 Dec24 Dec25
Debt-to-EBITDA
-2.20 -2.41 -2.69

Innovacell Quarterly Data
Dec23 Dec24 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial N/A -2.36 -2.29 -0.70 N/A

TSE:504A vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Innovacell's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovacell Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovacell's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Innovacell's Debt-to-EBITDA falls into.


TSE:504A
10GF Score
Innovacell Inc TSE:504A
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innovacell Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Innovacell's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(103.766 + 5092.411) / -1932.648
=-2.69

Innovacell's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(117.163 + 2057.805) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Innovacell Business Description

Address 3-5-11 Kamiosaki, Meguro Villa Garden, 5th floor, Shinagawa-ku, Tokyo, JPN, 141-0021
Innovacell Inc is engaged in the development, manufacturing, and sale of regenerative medicine products for the treatment of conditions including fecal and urinary incontinence. Its activities include researching potential therapeutic candidates, developing formulations, and commercializing products in the markets. The company is working on the development and commercialization of the following three cell therapy pipelines targeting incontinence (fecal and urinary incontinence): ICEF15, ICEF16, and ICES13.
10GF Score

Get the complete analysis for TSE:504A

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円583.00
Price